Delcath Systems Inc (DCTH)

[Rapture2020]

FAAAAAADAAAAAAH!!!

1. OS: 896,994 shares - ignore fake news that dilution is occurring.

2. Slowed Q over Q cash burn. NICE!

3. Revenue from European sales for the quarter was $0.7 million.

4. DCTH has 240 patients enrolled in FOCUS - ignore fake news that trials are being canceled all over the U.S.

5. ECONOMIES OF SCALE!!! Need more supply to handle the anticipated increase in demand= secured a commercial supply of melphalan hydrochloride for injection through an agreement with Tillomed Laboratories.

6. ICC Trial (ALIGN) registration begins. This puppy is a monster--the market is between $900,000,000 - $1,200,000,000 ANNUALLY.

7. Don't sleep on Right to Try; oh, and offering is going to surprise, IMO.

8. FOCUS TRIAL GETS ANOTHER GREEN LIGHT TO PROCEED FROM THE FDA!!!

Each day that passes gets us closer to FDA approval.

IT'S ALL COMING TOGETHER!